« Go Back

Slone Partners Enhances its Footprint in Private Equity, Healthcare, and Nonprofit Sector Executive Search

Senior Leaders Bridget Burke and Kate Portand Promoted to SVP & Practice Leaders

SOUTH RIDING, VA. – January 18, 2024 – Slone Partners, a nationwide executive search firm for life sciences, healthcare, and cybersecurity organizations, is expanding its footprint in the private equity, healthcare, and nonprofit executive search markets with the promotion of two senior leaders.

Bridget Burke, who previously served as the company’s Chief Business Officer, has been named Senior Vice President & Practice Leader, Healthcare, Nonprofits & Social Impact, and Kate Portand has been elevated to Senior Vice President & Practice Leader, Private Equity. The promotions reflect Slone Partners’ commitment to deepening its relationships with companies, organizations, and leaders in these important sectors.

An accomplished business leader and fundraiser with more than 20 years of experience in both the for-profit and nonprofit sectors, Burke has maintained her focus on the intersection of philanthropy, health equity, and mission-driven work. She is an integral part of the Slone Partners’ leadership team where she helps to elevate and expand the company’s business portfolio. Earlier in her career, Burke served as Director of Executive Search at The Angeletti Group, where she was the lead client manager to educational institutions, hospitals, and religious and community organizations, providing a range of philanthropic counsel including strategic planning, board management, development office assessments, and feasibility studies.

“The nonprofit and social impact sector is changing rapidly as it responds to evolving social and market demands to confront the many different challenges that we face. Hospitals, health systems, and academic medical centers are also facing new challenges as they push new boundaries of research, diagnostics, and treatment. Organizations in these sectors are in stiff competition for both dollars and leaders who can drive them forward, remaining laser-focused on the mission while also raising the money they need to scale,” said Burke. “My role as SVP and Practice Leader is to help match these worthy organizations with exceptional leaders who are prepared to roll up their sleeves and execute.”

Portland has more than 20 years of experience in recruiting, executive search, investment banking, and healthcare consulting. Prior to joining Slone Partners, she was Head of Executive Talent at Water Street, a Chicago-based private equity firm with a focus on investing in the healthcare and life sciences sectors. Previously, she was the Vice President of Human Capital at GTCR where she oversaw human resources and recruiting for the investment teams. She also spent several years in search, supporting private equity firms in their hiring needs before going in-house. Portland began her career as an investment banking analyst at both Goldman Sachs and Citigroup and as a healthcare consultant. She has always had a passion for the intersection of investing and healthcare, graduating from The Wharton School of The University of Pennsylvania with a BS in Economics, concentrating in Finance and Healthcare Management.

“Our unique value proposition as an executive search firm is our full-service model. Not only do we lead searches for Board Directors and the C-Suite at investor backed firms, we also partner with them to build out their teams across all key functional areas. In addition, we support our private equity clients with hiring for their Investment teams. What I bring to the table with my years of private equity experience is deep knowledge of what makes for a good leader in private equity and their portfolio companies,” said Portland.

“I see a tremendous opportunity for Slone Partners to further broaden its scope in the healthcare, nonprofit and social impact, and private equity sectors,” said Leslie Loveless, Slone Partners CEO and Managing Partner. “As Practice Leaders with valuable experience and relationships in these areas, Bridget and Kate are ideally suited to expand our impact in these business verticals as we serve the executive talent needs of companies, systems, and organizations in the years to come.”

ABOUT SLONE PARTNERS
Founded in 2000, Slone Partners is the premier executive search firm that delivers top diverse and visionary leaders who build amazing life sciences, healthcare, and cybersecurity organizations. With a nationwide presence in the most active industry hubs, we specialize in discovering and placing world-class C-Suite leadership, executive, and upper management talent with experience, conviction, and cultural competence in emerging and well-established companies. Our portfolio of executive search and advisory services includes diversity, equity, and inclusion strategy, education, and training. Slone Partners proudly holds the designation as a Certified LGBT Business Enterprise™ by the National Gay & Lesbian Chamber of Commerce (NGLCC) and has earned recognition as a Top Executive Search Firm and a Top 20 Diversity and Inclusion Services firm by Manage HR. To learn more about Slone Partners’ value proposition and processes, visit https://www.slonepartners.com or call 888.784.3422.

« Go Back

Slone Partners Places Gregory C. Critchfield, M.D., M.S., as Co-CEO at EarlyDiagnostics

Proven business leader brings more than 30 years of operational and strategic experience

SOUTH RIDING, VA. – January 16, 2024 – Slone Partners, a nationwide executive search firm for life sciences, healthcare, and cybersecurity organizations, has announced the placement of Gregory C. Critchfield as Co-Chief Executive Officer (CEO) at EarlyDiagnostics (EarlyDx), the leading company in world-class liquid biopsy methylome detection of early cancer.

Critchfield is a proven business leader with more than 30 years of operational and strategic experience in several diagnostic enterprises. As a Board member, former Chairman, and CEO, he led Sera Prognostics from its early financing stages in 2010 through and beyond its successful IPO in 2021. Prior to his tenure with Sera, Critchfield served as President of Myriad Genetic Laboratories, where he and his team built Myriad into one of the world’s leading molecular diagnostics companies by commercializing DNA sequencing genetic tests for inherited cancer predisposition including breast, ovarian, colorectal, and endometrial cancers. Critchfield also served as Chief Medical and Science Officer at Quest Diagnostics, Inc., where he oversaw medical and innovation activities in its transition from Corning Clinical Laboratories to a publicly traded company.

“Greg Critchfield is a highly accomplished and respected life sciences executive with the deep knowledge and experience needed to drive a growth-focused company forward,” said Leslie Loveless, Slone Partners CEO and Managing Partner. “He will be a tremendously valuable addition to the EarlyDiagnostics leadership team as the company prepares to launch its new commercial products.”

“We are thrilled to welcome Greg to EarlyDx,” said Jasmine Zhou, Co-founder and Co-CEO of EarlyDiagnostics, Inc. “He possesses the vision, leadership, and a proven reputation to help transform startups into commercially active growth companies. With this addition to our experienced leadership team, EarlyDx is well-positioned to drive forward into our next phase of growth and success.”

Critchfield holds a Bachelor’s of Science degree in Microbiology from Brigham Young University; an M.D. from the University of Utah; and an M.S. in Biophysical Sciences from the University of Minnesota.

ABOUT SLONE PARTNERS
Founded in 2000, Slone Partners is the premier executive search firm that delivers top diverse and visionary leaders who build amazing life sciences, healthcare, and cybersecurity organizations. With a nationwide presence in the most active industry hubs, we specialize in discovering and placing world-class C-Suite leadership, executive, and upper management talent with experience, conviction, and cultural competence in emerging and well-established companies. Our portfolio of executive search and advisory services includes diversity, equity, and inclusion strategy, education, and training. Slone Partners proudly holds the designation as a Certified LGBT Business Enterprise™ by the National Gay & Lesbian Chamber of Commerce (NGLCC) and has earned recognition as a Top Executive Search Firm and a Top 20 Diversity and Inclusion Services firm by Manage HR. To learn more about Slone Partners’ value proposition and processes, visit https://www.slonepartners.com or call 888.784.3422.

ABOUT EARLYDIAGNOSTICS
EarlyDiagnostics (EarlyDx) is devoted to providing accurate, affordable, and non-invasive liquid biopsy tests for early cancer detection and precision medicine. Its proprietary technologies for cost-effective cell-free DNA methylome sequencing, in combination with its powerful AI algorithms, have achieved high performance results in multi-cancer early detection and localization. The company’s scientific team has a number of key publications in highly reputable journals that demonstrate significant contributions to science and leadership in the field. EarlyDx aims to launch commercial products beginning in 2024 to provide early cancer detection and precision medicine testing for doctors and patients, with the goal of improving the health outcomes of patients.

« Go Back

Slone Partners Announces Promotions for Several High-Performing Senior Leaders

SVP, VPs, and COO Named Partners as Company Propels to Next Level of Executive Search

SOUTH RIDING, VA. – January 9, 2024 – Slone Partners, a nationwide executive search firm for life sciences, healthcare, and cybersecurity organizations, has announced promotions for Senior Vice President (SVP) Kim Wilson, Vice Presidents (VPs) Kim Feitosa, Jennifer Lemasters, and Sona Stroud, and Chief Operating Officer (COO) Chrystie Chapman, all of whom are becoming Partners in the firm.

With her promotion to SVP, Executive Search, and Partner, Kim Wilson will continue drawing on her more than 20 years of experience in the healthcare and life sciences industries in placing key strategic leaders in biotech, life sciences, healthcare, digital health, and medical technology sectors.  Wilson possesses extensive expertise in placing VP-level and C-suite roles in operations, finance, commercialization, legal, clinical, scientific, reimbursement, and regulatory affairs, as well as placing board directors.

Kim Feitosa, who has more than 30 years of experience in life sciences marketing, sales, business development, and talent recruitment, is promoted to SVP, Executive Search, and Partner. In her role, Feitosa focuses on placing innovative scientific, clinical, and business leaders who bring their company’s services and products to market for the benefit of patients.

Jennifer Lemasters, whose tenure at Slone Partners dates back to 2011, is promoted to SVP, Executive Search, and Partner. Her deep understanding of the life sciences and healthcare markets and knowledge of the demands placed on each leadership role give her the perspectives needed to develop a thorough assessment of each candidate. In her role, Lemasters will continue to deliver a wide range of premier talent to clients including executive leaders in all disciplines.

With more than 20 years of experience in life sciences and healthcare, Sona Stroud brings her extensive market knowledge and a stellar track record of successful key executive and leadership placements to her new role as SVP, Executive Search, and Partner. Her focus remains on securing top talent in all functional areas including scientific, clinical, and administrative roles.

Chrystie Chapman, who joined Slone Partners in 2007 and has served as COO since 2021, was promoted to Partner last May. She is a highly respected and accomplished business leader with more than 20 years of experience working with small businesses in the healthcare and executive search fields. As COO, Chapman is responsible for the company’s financial, human resources, and operational functions, and is a key member of Slone Partners’ executive team.

“These promotions are an acknowledgment of the tireless and dedicated efforts of senior leaders who have helped propel Slone Partners into the eminent position it now holds in the executive search market,” said Leslie Loveless, Slone Partners CEO. “I am extremely proud of their exceptional work and am elated to elevate them to Partners as we continue to grow and serve the executive search needs of our innovative clients in the life sciences, healthcare, and cybersecurity industries.”

“I am honored to join the Partnership team at Slone Partners along with such a distinguished group of colleagues whose commitment and devotion have been an invaluable asset to our company,” said Chapman. “Together, we look forward to achieving even greater success in our collective future.”

ABOUT SLONE PARTNERS

Founded in 2000, Slone Partners is the premier executive search firm that delivers top diverse and visionary leaders who build amazing life sciences, healthcare, and cybersecurity organizations. With a nationwide presence in the most active industry hubs, we specialize in discovering and placing world-class C-Suite leadership, executive, and upper management talent with experience, conviction, and cultural competence in emerging and well-established companies. Our portfolio of executive search and advisory services includes diversity, equity, and inclusion strategy, education, and training. Slone Partners proudly holds the designation as a Certified LGBT Business Enterprise™ by the National Gay & Lesbian Chamber of Commerce (NGLCC) and has earned recognition as a Top Executive Search Firm and a Top 20 Diversity and Inclusion Services firm by Manage HR. To learn more about Slone Partners’ value proposition and processes, visit https://www.slonepartners.com or call 888.784.3422.

« Go Back

Slone Partners Places Jeremy Bender, Teresa Bitetti, and David Meek as Members of the Board of Directors at Fusion Pharmaceuticals

Trio brings extraordinary business and scientific experience to the Fusion Board

SOUTH RIDING, VA. – October 31, 2023 – Slone Partners, a nationwide executive search firm for life sciences, healthcare, and cybersecurity organizations, has announced the placements of Jeremy Bender, Ph.D., MBA, Teresa Bitetti, MBA, and David Meek as members of the Board of Directors at Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing next-generation radiopharmaceuticals as precision medicines for the treatment of cancer.

Dr. Bender currently serves as Chief Executive Officer (CEO) of Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company focused on pediatric cancer. Previously, he served as Vice President of Corporate Development at Gilead Sciences, overseeing acquisitions, partnerships, and investments. Dr. Bender also served as CEO at Tizona Therapeutics, Chief Business Officer at Sutro Biopharma, and Vice President of Corporate Development at Allos Therapeutics. He currently sits on the Board of Mereo BioPharma as an Independent Board Member.

Ms. Bitetti currently serves as President of the Global Oncology Business Unit of Takeda. Previously, she held various roles of increasing responsibility at Bristol-Myers Squibb Company (BMS), including as Senior Vice President, Head of Worldwide Oncology Commercialization. At BMS, Ms. Bitetti also served as Senior Vice President and Head of the U.S. Oncology business, President and General Manager of BMS Canada, and Worldwide Head of the BMS Virology business. She currently serves on the board of Osmol Therapeutics as an independent director.

Mr. Meek most recently served as CEO and Member of the Board of Directors of Mirati Therapeutics. Prior to this role, he served as the President, CEO, and Board Member of FerGene, and CEO and Board Member of Ipsen. Mr. Meek was previously an Executive Vice President and President of Oncology at Baxalta Incorporated in the leadup to the acquisition by Shire, and Chief Commercial Officer of Endocyte. He previously held executive leadership roles at Novartis Pharmaceuticals Corporation and Novartis Oncology. Mr. Meek previously served on the Board of Directors of Entasis Therapeutics (acquired by Innoviva) and currently serves on the Board of Directors of uniQure N.V.

“Jeremy Bender, Teresa Bitetti, and David Meek are all very accomplished and highly respected leaders in the fields of biopharmaceuticals, oncology, and therapeutics,” said Leslie Loveless, Slone Partners CEO. “They bring extraordinary business and scientific experience and knowledge to the Board at a very exciting time in the company’s history.”

“We are excited to welcome Jeremy, Teresa, and David to Fusion’s Board of Directors, each bringing an exceptional breadth of experience and track record of success in oncology drug development, business development, and commercialization. Their experiences introducing innovative therapies to cancer patients as leaders of top-tier oncology companies will be invaluable as we advance our pipeline, particularly our lead program FPI-2265, which is on track to be the first actinium-based PSMA targeted alpha therapy (TAT) to market,” said Fusion Chief Executive Officer John Valliant, Ph.D. “Fusion is undergoing an exciting evolution to a later stage radiopharmaceutical company and with these appointments we are transforming our Board to maximize the value generation of our strategy.”

Dr. Bender holds a B.S. in Biological Sciences from Stanford University, a Ph.D. in Microbiology and Immunology from the University of Colorado, and an M.B.A. from the MIT Sloan School of Management. Ms. Bitetti holds a B.A. from Wellesley College and an M.B.A. from the Darden School of Business at the University of Virginia. Mr. Meek holds a B.A. from the University of Cincinnati.

ABOUT SLONE PARTNERS

Founded in 2000, Slone Partners is the premier executive search firm that delivers top diverse and visionary leaders who build amazing life sciences, healthcare, and cybersecurity organizations. With a nationwide presence in the most active industry hubs, we specialize in discovering and placing world-class C-Suite leadership, executive, and upper management talent with experience, conviction, and cultural competence in emerging and well-established companies. Our portfolio of executive search and advisory services includes diversity, equity, and inclusion strategy, education, and training. Slone Partners proudly holds the designation as a Certified LGBT Business Enterprise™ by the National Gay & Lesbian Chamber of Commerce (NGLCC) and has earned recognition as a Top Executive Search Firm and a Top 20 Diversity and Inclusion Services firm by Manage HR. To learn more about Slone Partners’ value proposition and processes, visit https://www.slonepartners.com or call 888.784.3422.

ABOUT FUSION PHARMACEUTICALS

Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Fusion connects alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha emitting payloads to tumors. Fusion’s clinical portfolio includes: FPI-2265 targeting prostate specific membrane antigen (PSMA) for metastatic castration resistant prostate cancer currently in a Phase 2 trial; FPI-1434 targeting insulin-like growth factor 1 receptor currently in a Phase 1 trial; and FPI-2059, a small molecule targeting neurotensin receptor 1 (NTSR1), currently in a Phase 1 trial. In addition to a robust proprietary pipeline, Fusion has a collaboration with AstraZeneca to jointly develop novel targeted alpha therapies (TATs) and combination programs between Fusion’s TATs and AstraZeneca’s DNA Damage Response Inhibitors (DDRis) and immuno-oncology agents. The Company recently received IND clearance for FPI-2068, the first novel TAT under the collaboration, which targets EGFR-cMET. Fusion has also entered into a collaboration with Merck to evaluate FPI-1434 in combination with Merck’s KEYTRUDA® (pembrolizumab) in patients with solid tumors expressing IGF-1R. To support Fusion’s growing pipeline of TATs, the Company has signed strategic actinium supply agreements with TRIUMF, Niowave, Inc. and BWXT Medical. For more information, visit the website: https://fusionpharma.com/.

« Go Back

Slone Partners Places Cynthia Pussinen as Chief Executive Officer and Member of the Board of Directors at Sernova Corporation

Industry veteran will lead the company’s next stage of growth and development

September 14, 2023 – Slone Partners, a nationwide executive search firm for life sciences, healthcare, and cybersecurity organizations, has announced the placement of Cynthia Pussinen as Chief Executive Officer (CEO) and a member of the Board of Directors at Sernova Corporation, a clinical-stage company and leader in cell therapeutics.

Pussinen’s expertise spans the drug development continuum from research through commercialization. She has led the development, licensure, commercialization, and/or subsequent delivery to patients of more than 15 new medical therapies for patients globally, including Obizur® (Antihemophilic Factor (Recombinant), Porcine Sequence), Eraxis® (anidulafungin), Zmax® (azithromycin extended-release) and LUXTURNA® (voretigene neparvovec-rzyl), the first gene therapy approved in both the United States and the European Union.

Most recently, Pussinen served as Chief Technical Officer for Spark Therapeutics, Inc., a fully integrated, commercial gene therapy company, and a member of the Roche Group. Prior to joining Spark in 2021, Pussinen’s leadership roles included six years with Ipsen Biomeasure and Ipsen Biosciences, U.S. R&D-focused subsidiaries of Ipsen, where she served as President and CEO. Pussinen previously served as Executive Vice President, Technical Development, Operations and Supply Chain for Actinium Pharmaceuticals, Inc. and as Global Vice President and General Manager, Life Sciences and Specialty Chemicals for Honeywell International.

“Cynthia Pussinen is an extremely accomplished and respected scientist and global pharmaceutical executive with an impressive track record of bringing innovative new products to market in various leadership roles at several highly acclaimed life sciences companies,” said Leslie Loveless, Slone Partners CEO. “She will make for a terrific addition to the Sernova leadership team and Board of Directors during a pivitol stage in the company’s evolution.”

“Sernova has demonstrated tremendous growth over the past several years as it has transitioned from a research company to one that is moving towards commercialization of a product for the treatment of multiple chronic diseases. As a united Board, we feel now is the time to bring in an industry leader with extensive experience with large pharmaceutical companies as well as entrepreneurial biotech and advanced therapeutics focused companies,” commented Brett Whalen, Chair of the Board of Directors of Sernova. “The skills that Ms. Pussinen brings to our company include over 25 years of global experience shepherding new therapies from development through commercialization across multiple conditions with sales measured in the billions.”

Pussinen earned a Master of Science in R&D management from Rensselaer Polytechnic Institute and a Bachelor of Science in chemistry, with a minor in engineering from the University of Connecticut.

ABOUT SLONE PARTNERS

Founded in 2000, Slone Partners is the premier executive search firm that delivers top diverse and visionary leaders who build amazing life sciences, healthcare, and cybersecurity organizations. With a nationwide presence in the most active industry hubs, we specialize in discovering and placing world-class C-Suite leadership, executive, and upper management talent with experience, conviction, and cultural competence in emerging and well-established companies. Our portfolio of executive search and advisory services includes diversity, equity, and inclusion strategy, education, and training. Slone Partners proudly holds the designation as a Certified LGBT Business Enterprise™ by the National Gay & Lesbian Chamber of Commerce (NGLCC) and has earned recognition as a Top Executive Search Firm and a Top 20 Diversity and Inclusion Services firm by Manage HR. To learn more about Slone Partners’ value proposition and processes, visit www.slonepartners.com or call 888.784.3422.

ABOUT SERNOVA CORPORATION

Sernova Corporation is a clinical-stage biotechnology company that is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. Sernova is currently focused on developing a ‘functional cure’ for insulin-dependent diabetes with its lead asset, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. On implantation, The Cell Pouch forms a natural vascularized tissue environment in the body for long-term survival and function of therapeutic cells that release essential factors that are absent or deficient in the bodies of patients with certain chronic diseases. Sernova’s Cell Pouch System has demonstrated its potential to be a ‘functional cure’ for people with T1D in an ongoing Phase 1/2 clinical study at the University of Chicago. Sernova is also advancing a proprietary technology in collaboration with the University of Miami to shield therapeutic cells from immune system attack with the goal to eliminate the need for chronic, systemic immunosuppression. For more information, visit the website: https://sernova.com/.

« Go Back

Slone Partners Places Christophe Arbet-Engels as Chief Medical Officer at X4 Pharmaceuticals

New CMO brings more than 20 years of experience in complex organizational settings

 SOUTH RIDING, VA. – August 31, 2023 – Slone Partners, a nationwide executive search firm for life sciences, biotechnology, and healthcare companies, today announced the successful placement of Christophe Arbet-Engels, MD, PhD, as Chief Medical Officer (CMO) at X4 Pharmaceuticals, Inc., a biopharmaceutical company developing novel small molecule therapeutics to benefit patients with diseases of the immune system.

Arbet-Engels previously served as CMO at several life science companies, including Neurogastrx, Millendo Therapeutics, and Poxel Pharmaceuticals, where he provided research and development leadership, advancing multiple candidates from pre-clinical through to late-stage clinical trials. Prior to these roles, he held a variety of senior medical and clinical positions at Biogen, Boehringer-Ingelheim Pharmaceuticals, Hoffmann-La Roche, Merck Research Laboratories, Aventis Pharmaceuticals, and Ligand Pharmaceuticals, where he led clinical development and registration, launch and lifecycle management efforts for several new medicines.

“Dr. Arbet-Engels is a highly respected and experienced global pharmaceutical executive with keen business acumen honed over more than 20 years serving in complex organizational settings,” said Leslie Loveless, Slone Partners CEO. “We are very pleased to have been able to place him at X4 where we believe his extraordinary drive, passion, and vision – and his proven track record of success – will make a wonderful addition to the company’s leadership team.”

“It was truly a pleasure collaborating with Slone Partners on the placement of Christophe as our new Chief Medical Officer,” said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals, “We very much value our relationship with the Slone team and consider them a valuable ongoing resource to X4 given their deep understanding of and high quality connections within the life science industry.”

ABOUT SLONE PARTNERS

Slone Partners delivers the leaders who build amazing and diverse life sciences and healthcare organizations – People Are Our Science®. Founded in 2000, Slone Partners specializes in delivering world-class C-suite leadership, executive, and upper management talent to the most promising and established biotech, diagnostics, research tools, healthcare, precision medicine, medical device, and laboratory services companies. With national and global clients, Slone Partners uniquely and precisely provides an array of executive search and advisory services, including diversity, equity, and inclusion strategy, to innovative life sciences and healthcare companies. To learn more about Slone Partners’ value proposition and processes, visit www.slonepartners.com or call 888.784.3422.

« Go Back

Slone Partners Places Robert McMahon as Member of Board of Directors at OraSure Technologies

New director brings more than 30 years of experience as a senior finance business leader

 SOUTH RIDING, VA. – August 10, 2023 – Slone Partners, a nationwide executive search firm for life sciences, biotechnology, and healthcare companies, has announced the placement of Robert McMahon as a member of the Board of Directors at OraSure Technologies, Inc., a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services.

McMahon has more than 30 years of experience as a senior finance business leader and currently serves as Senior Vice President and Chief Financial Officer (CFO) for Agilent Technologies where he is responsible for finance, audit, treasury, tax, and investor relations.

Prior to his work for Agilent, McMahon spent four years serving as CFO for Hologic, where he led a team that reshaped the product portfolio and significantly improved company performance and profitability. He also spent more than 20 years at Johnson & Johnson where he held numerous leadership positions with key responsibilities that spanned corporate finance, financial planning and analysis, financial roadmaps, portfolio optimization, enterprise valuation, divestiture management, and business leadership. At OraSure, McMahon will serve as a Class II Director with an initial term expiring at the Company’s 2026 Annual Meeting of Stockholders.

“Robert McMahon has extensive and impressive leadership experience in high-performing organizations, where he has driven growth and increased profitability,” said Leslie Loveless, Slone Partners CEO. “He brings an extraordinary depth of knowledge through a highly refined financial management lens to the Board of Directors at OraSure.”

“We are pleased to welcome Robert McMahon to our Board and recognize the tremendous value that he will contribute to our team,” said Mara Aspinall, Chair of the Board of Directors of OraSure. “Bob’s healthcare expertise, complemented by the depth of his financial acumen, comes at the right time in OraSure’s transformation journey. Our strong leadership team led by Carrie Eglinton Manner, President and CEO, have made important strides in strengthening our foundation, elevating our core growth, and accelerating our profitability.”

McMahon holds a Masters of Business Administration degree from the University of Central Florida and a Bachelor’s degree from the University of Florida.

ABOUT SLONE PARTNERS

Slone Partners delivers the leaders who build amazing and diverse life sciences and healthcare organizations – People Are Our Science®. Founded in 2000, Slone Partners specializes in delivering world-class C-suite leadership, executive, and upper management talent to the most promising and established biotech, diagnostics, research tools, healthcare, precision medicine, medical device, and laboratory services companies. With national and global clients, Slone Partners uniquely and precisely provides an array of executive search and advisory services, including diversity, equity, and inclusion strategy, to innovative life sciences and healthcare companies. To learn more about Slone Partners’ value proposition and processes, visit www.slonepartners.com or call 888.784.3422.

ABOUT ORASURE TECHNOLOGIES

OraSure Technologies, Inc. empowers the global community to improve health and wellness by providing access to accurate, essential information. OraSure, together with its wholly-owned subsidiaries, DNA Genotek, Diversigen, and Novosanis, provides its customers with end-to-end solutions that encompass tools, services, and diagnostics. The OraSure family of companies is a leader in the development, manufacture, and distribution of rapid diagnostic tests, sample collection and stabilization devices, and molecular services solutions designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharma, commercial entities, and direct to consumers. For more information on OraSure Technologies, please visit www.orasure.com.

Logo Slone Partners
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.